Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BMGLNASDAQ:OPGNNASDAQ:RNLXNASDAQ:SERA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBMGLBasel Medical Group$2.67-1.5%$3.58$0.91▼$9.40$49.28MN/A14.95 million shs356,669 shsOPGNOpGen$4.88$4.73$0.53▼$5.25$49.13M-1.689,626 shs38 shsRNLXRenalytix$0.21$0.23$0.18▼$2.40$17.18M2.721.45 million shs934,496 shsSERASera Prognostics$1.88+2.2%$2.35$1.37▼$9.13$70.83M0.71153,408 shs264,870 shs10 Stocks Set to Soar in Summer 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBMGLBasel Medical Group0.00%-43.19%+34.17%+266,999,900.00%+266,999,900.00%OPGNOpGen0.00%-1.61%-0.20%+82.77%+92.89%RNLXRenalytix0.00%0.00%0.00%0.00%-58.46%SERASera Prognostics0.00%+5.62%-11.32%-50.40%-74.14%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBMGLBasel Medical GroupN/AN/AN/AN/AN/AN/AN/AN/AOPGNOpGenN/AN/AN/AN/AN/AN/AN/AN/ARNLXRenalytixN/AN/AN/AN/AN/AN/AN/AN/ASERASera Prognostics0.3114 of 5 stars0.02.00.00.01.12.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBMGLBasel Medical Group 0.00N/AN/AN/AOPGNOpGen 0.00N/AN/AN/ARNLXRenalytix 3.00Buy$3.001,348.58% UpsideSERASera Prognostics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBMGLBasel Medical GroupN/AN/AN/AN/AN/AN/AOPGNOpGen$2.67M18.38N/AN/A($11.55) per share-0.42RNLXRenalytix$2.29M7.50N/AN/A($0.10) per share-2.07SERASera Prognostics$115K615.87N/AN/A$1.40 per share1.34Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBMGLBasel Medical GroupN/AN/A0.00∞N/AN/AN/AN/AN/AOPGNOpGen-$32.67MN/A0.00∞N/A-1,140.36%N/A-287.58%7/7/2025 (Estimated)RNLXRenalytix-$33.46M-$0.39N/A∞N/A-1,461.60%N/A-281.40%N/ASERASera Prognostics-$32.90M-$0.94N/AN/AN/A-28,685.22%-51.35%-37.21%8/6/2025 (Estimated)Latest RNLX, SERA, BMGL, and OPGN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025SERASera Prognostics-$0.24-$0.20+$0.04-$0.20$0.06 million$0.04 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBMGLBasel Medical GroupN/AN/AN/AN/AN/AOPGNOpGenN/AN/AN/AN/AN/ARNLXRenalytixN/AN/AN/AN/AN/ASERASera PrognosticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBMGLBasel Medical GroupN/AN/AN/AOPGNOpGenN/A5.455.45RNLXRenalytixN/A0.530.53SERASera PrognosticsN/A2.022.02Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBMGLBasel Medical GroupN/AOPGNOpGen2.68%RNLXRenalytix9.92%SERASera Prognostics54.64%Insider OwnershipCompanyInsider OwnershipBMGLBasel Medical GroupN/AOPGNOpGen43.80%RNLXRenalytix18.30%SERASera Prognostics13.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBMGLBasel Medical Group3618.45 millionN/AN/AOPGNOpGen10010.07 million4.70 millionNot OptionableRNLXRenalytix10082.96 million63.06 millionOptionableSERASera Prognostics12037.67 million32.59 millionOptionableRNLX, SERA, BMGL, and OPGN HeadlinesRecent News About These CompaniesSera Prognostics, Inc. (NASDAQ:SERA) CEO Sells $32,950.06 in StockJune 12, 2025 | insidertrades.comInsider Selling: Sera Prognostics, Inc. (NASDAQ:SERA) CEO Sells 23,042 Shares of StockJune 11, 2025 | marketbeat.comWe Think Sera Prognostics (NASDAQ:SERA) Needs To Drive Business Growth CarefullyJune 10, 2025 | finance.yahoo.comsera prognostics announces board elections and auditor ratificationJune 7, 2025 | investing.comSera Prognostics (NASDAQ:SERA) Rating Lowered to "Sell" at Wall Street ZenJune 7, 2025 | marketbeat.comAfter Plunging 43.9% in 4 Weeks, Here's Why the Trend Might Reverse for Sera Prognostics (SERA)May 29, 2025 | zacks.comSERA PROGNOSTICS TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCESMay 29, 2025 | prnewswire.comSera Prognostics, Inc.: Sera Prognostics Reports First Quarter 2025 Financial ResultsMay 26, 2025 | finanznachrichten.deSERA PROGNOSTICS TO PRESENT AT RBC GLOBAL HEALTHCARE CONFERENCEMay 14, 2025 | prnewswire.comSera Prognostics, Inc. (NASDAQ:SERA) Q1 2025 Earnings Call TranscriptMay 13, 2025 | msn.comDown -30.54% in 4 Weeks, Here's Why Sera Prognostics (SERA) Looks Ripe for a TurnaroundMay 13, 2025 | zacks.comSera Prognostics Inc (SERA) Q1 2025 Earnings Call TranscriptMay 11, 2025 | seekingalpha.comSera Prognostics, Inc. (NASDAQ:SERA) CFO Sells $15,552.56 in StockMay 10, 2025 | insidertrades.comSera Prognostics, Inc.: Sera Prognostics Appoints Lee Anderson As Chief Commercial OfficerMay 9, 2025 | finanznachrichten.deEarnings call transcript: Sera Prognostics reports Q1 2025 earnings beatMay 9, 2025 | investing.comSera Prognostics Reports Q1 Revenues of $38K as Preterm Birth Test Commercialization ProgressesMay 9, 2025 | 360dx.comWhat I Wish I Knew: The Truth About Preterm Birth for Black WomenMay 9, 2025 | blackdoctor.orgSERA PROGNOSTICS APPOINTS LEE ANDERSON AS CHIEF COMMERCIAL OFFICERMay 8, 2025 | prnewswire.comSera Prognostics Reports Q1 2025 Financial ResultsMay 8, 2025 | tipranks.comSera Prognostics, Inc. (SERA) Reports Q1 Loss, Misses Revenue EstimatesMay 7, 2025 | zacks.comSERA PROGNOSTICS REPORTS FIRST QUARTER 2025 FINANCIAL RESULTSMay 7, 2025 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeRNLX, SERA, BMGL, and OPGN Company DescriptionsBasel Medical Group NASDAQ:BMGL$2.67 -0.04 (-1.48%) As of 06/18/2025 04:00 PM EasternBasel Medical Group Ltd. is an investment holding company, which engages in providing orthopedic surgeries, medical care, and diagnosis services. Its services include orthopedic surgeries, medical care, rehabilitative therapy, physiotherapy, non-surgical treatments, medical diagnosis, magnetic resonance imaging, general surgery, x-ray, lump removal, sports medicine, and total hip replacement. The company was founded by Man Hing Yip on August 10, 2023 and is headquartered in Singapore.OpGen NASDAQ:OPGN$4.88 0.00 (0.00%) As of 06/18/2025OpGen, Inc., a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits. The company's products also comprise ARES Technology Platform, including ARES reference database on antimicrobial resistance using next generation sequencing technology and artificial intelligence powered bioinformatics solutions for antibiotic response prediction; and Unyvero Platform, an automated sample-to-answer molecular diagnostics platform that integrates automated sample preparation, analysis, and identification of disease relevant pathogens and antibiotic resistance markers. It also utilizes molecular diagnostics and informatics to help combat infectious diseases. The company helps clinicians with information about life threatening infections to enhance patient outcomes, and to decrease the spread of infections caused by multidrug-resistant microorganisms. OpGen, Inc. has a collaboration with the New York State Department of Health and ILÚM Health Solutions, LLC to develop a research program to detect, track, and manage antimicrobial-resistant infections at healthcare institutions. The company was incorporated in 2001 and is headquartered in Rockville, Maryland.Renalytix NASDAQ:RNLXRenalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record systems to generate a unique patient risk score. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. Renalytix Plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; and Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers. The company also has a partnership agreement with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to implement an advanced clinical care model designed to improve kidney health and reduce kidney disease progression and kidney failure. The company was formerly known as Renalytix AI plc and changed its name to Renalytix Plc in June 2021. Renalytix Plc was incorporated in 2018 and is based in New York, New York.Sera Prognostics NASDAQ:SERA$1.88 +0.04 (+2.17%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$1.88 0.00 (0.00%) As of 06/18/2025 06:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preterm birth, preeclampsia, molecular time-to-birth, predictive analytics, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Robinhood Director Sells Millions, But HOOD Stock Eyes Gains Coinbase Stock Pops as Senate Passes GENIUS Stablecoin Bill Chime’s Smart IPO: Half the Valuation, Double the Strength 3 Tech Stocks With High and Rising Institutional Interest Salesforce Raises Prices: 3 Reasons Its Stock Price Will Follow Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
